Trial Profile

Ph 1/2 Open-label, Multi-center, FIH Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics & Antitumor Activity of STX-001 Via Intratumoral Injection in Pts w Advanced Solid Tumors as Monotherapy or Combination w Pembrolizumab

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; STX 001 (Primary)
Indications Malignant melanoma; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; First in man
Sponsors Strand Therapeutics

28 May 2025 Interim results presented in a Strand Therapeutics media release.
28 May 2025 According to Strand Therapeutics media release, the company will present interim results from this trial at The 2025 ASCO Annual Meeting
28 May 2025 According to Strand Therapeutics media release, as of the April 3rd, 2025 data cutoff, the trial had enrolled 22 patients across multiple sites in the United States and Australia.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com